

Financial indicators (Sawai Group Holdings Co., Ltd. and its subsidiaries)

Japanese-GAAP		FY2010	FY2011	FY2012	FY2013	FY2014	FY2015	FY2016
For the fiscal year								
Net sales	Millions of yen	63,853	67,603	80,503	89,824	105,454	123,492	132,428
Cost of sales	Millions of yen	33,736	34,411	42,511	48,353	60,048	71,858	80,309
Gross profit	Millions of yen	30,117	33,192	37,992	41,471	45,406	51,634	52,119
Selling, general and administrative expenses	Millions of yen	16,531	18,188	20,607	22,380	24,718	28,449	31,486
Operating income	Millions of yen	13,586	15,004	17,385	19,091	20,688	23,185	20,633
Profit before income taxes	Millions of yen	12,289	14,928	18,098	18,990	20,298	23,092	19,871
Profit attributable to owners of parent	Millions of yen	7,183	9,026	12,022	12,193	14,053	17,156	15,914
Research and development (R&D) expenses	Millions of yen	3,902	4,317	4,551	5,170	6,110	8,019	10,208
Capital expenditures	Millions of yen	2,805	4,599	4,599	7,353	13,251	17,775	16,194
Depreciation and amortization	Millions of yen	3,066	3,389	3,793	4,989	5,863	7,044	8,645
At fiscal year-end								
Total assets	Millions of yen	117,056	123,400	127,843	149,348	166,180	206,492	221,539
Inventories	Millions of yen	21,218	25,780	29,529	39,182	44,663	55,668	61,777
Total current liabilities	Millions of yen	25,811	26,932	30,105	39,097	42,209	50,078	54,876
Total long-term liabilities	Millions of yen	40,382	37,893	36,258	8,949	11,572	30,692	29,063
Net assets	Millions of yen	50,863	58,575	61,480	101,302	112,399	125,722	137,600
Cash flows								
Net cash provided by operating activities	Millions of yen	5,937	7,814	12,256	13,422	12,112	19,975	20,628
Net cash used in investing activities	Millions of yen	-20,362	-2,371	-1,373	-8,283	-14,123	-22,937	-16,207
Net cash provided by (used in) financing activities	Millions of yen	24,756	-4,578	-10,970	-178	-922	13,473	-6,740
Cash and cash equivalents at end of year	Millions of yen	19,805	20,671	20,584	25,537	22,604	33,096	30,771
Financial Indicators								
Ratio of R&D expenses to sales	%	6.1	6.4	5.7	5.8	5.8	6.5	7.7
Return on equity	%	15.1	16.5	20.1	15.0	13.2	14.4	12.1
Shareholders' equity to total assets	%	43.4	47.4	48.0	67.8	67.6	60.8	62.0
Per share information								
Net income—basic	Yen	228.04	285.25	386.71	365.18	382.26	465.57	431.65
Net income—diluted	Yen	203.67	235.07	318.17	330.41	381.85	465.25	431.39
Cash dividends applicable to period	Yen	55.00	70.00	85.00	95.00	105.00	120.00	130.00
Net assets	Yen	1,605.16	1,846.84	2,027.15	2,755.29	3,053.29	3,405.20	3,722.90

IFRS	FY2016	FY2017	FY2018	FY2019	FY2020
Revenue	132,392	168,068	184,341	182,537	187,219
Cost of sales	80,548	98,628	109,442	109,037	114,785
Gross profit	51,844	69,440	74,899	73,500	72,434
Selling, general and administrative expenses (including research and development expenses)	28,497	47,264	49,051	46,862	53,820
Operating profit	22,943	22,209	25,798	26,793	18,888
Profit before tax	22,757	20,251	25,666	26,497	18,460
Profit attributable to owners of the Company	17,969	14,017	19,376	19,279	12,340
Research and development expenses	7,238	14,533	16,671	13,487	13,883
Capital expenditures	18,839	16,807	10,709	18,173	21,124
Depreciation and amortization	8,520	14,239	16,280	17,954	18,291
Total assets	225,609	358,453	372,889	384,814	393,341
Inventories	61,924	65,217	63,449	75,460	79,120
Total current liabilities	57,668	74,579	72,826	82,715	80,452
Total non-current liabilities	26,704	81,433	76,861	68,413	72,139
Total equity	141,237	202,441	223,204	233,686	240,750
Cash flows from operating activities	23,270	28,472	42,923	30,256	31,857
Cash flows used in investing activities	-18,827	-127,900	-16,820	-18,173	-21,794
Cash flows from (used in) financing activities	-6,761	108,597	-9,513	-12,747	-11,991
Cash and cash equivalents at the end of the year	30,771	39,992	57,067	56,082	54,269
Ratio of research and development expenses to revenue	5.5	8.6	9.0	7.4	7.4
Return on equity attributable to owners of the Company	13.4	8.7	10.2	9.4	5.8
Ratio of equity attributable to owners of the Company to total assets	62.6	50.6	53.4	54.6	55.5
Basic earnings per share	487.38	360.49	442.62	440.37	281.80
Diluted earnings per share	487.08	360.26	442.32	440.00	281.51
Dividends per share	130.00	130.00	135.00	130.00	130.00
Equity attributable to owners of the Company per share	3,830.84	4,143.15	4,551.50	4,796.40	4,984.51

Non-financial indicators (Sawai Pharmaceutical Co., Ltd.)

		FY2010	FY2011	FY2012	FY2013	FY2014	FY2015	FY2016
Sales volume	Billion tablets	4.6	4.7	5.7	6.5	8.0	8.9	10.2
Production capacity	Billion tablets	5.5	6.0	8.0	8.6	10.0	11.3	15.0
Number of new products launched		39	39	32	23	28	25	18
Number of patents held		8	8	9	14	19	21	23
Number of GMP audits conducted by Sawai Pharmaceutical		—	—	—	—	—	—	—
Number of employees		912	991	1,050	1,121	1,239	1,490	2,502
Number of female employees in managerial positions		—	—	—	—	10	10	11
Ratio of female employees in managerial positions	%	—	—	—	—	5.2	4.5	4.5
Energy Used	Crude oil conversion kℓ	—	—	—	—	20,473	26,781	30,914

	FY2016	FY2017	FY2018	FY2019	FY2020
Sales volume	10.2	10.6	11.9	12.4	13.3
Production capacity	15.0	15.5	15.5	15.5	15.5
Number of new products launched	18	43	33	12	44
Number of patents held	23	26	31	36	37
Number of GMP audits conducted by Sawai Pharmaceutical	164	100	110	133	124
Number of employees	2,502	3,252	3,131	3,066	3,003
Number of female employees in managerial positions	11	14	15	15	15
Ratio of female employees in managerial positions	4.5	5.5	6.0	6.1	5.8
Energy Used	30,914	31,948	32,336	31,015	30,130

Notes 1. Capital expenditures are presented on a cash flow basis.
 2. As the Company split its common stock two for one on October 1, 2013, amounts per common share for fiscal 2011 – fiscal 2013 were recalculated to reflect the share split.
 3. The Company has adopted International Financial Reporting Standards (IFRS) from fiscal 2017.

4. Dividend per share in fiscal 2018 included our 90th anniversary commemorative dividend of 5 yen.
 5. In fiscal 2020, non-current liabilities for guarantee deposits were transferred to current liabilities as minor errors were discovered with the current / non-current classification. Information for FY 2016 through FY 2019 (IFRS) has therefore been revised and reprinted.